Literature DB >> 1709693

Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles.

N E Kohl1, R E Diehl, E Rands, L J Davis, M G Hanobik, B Wolanski, R A Dixon.   

Abstract

To generate nonpathogenic viral particles which express active human immunodeficiency virus type 1 (HIV-1) protease (PR), plasmids containing sequences from the genomes of HIV-1 and Moloney murine leukemia virus (M-MuLV) were constructed. Either the PR coding region alone; the gag, PR, and reverse transcriptase protein-coding regions; or the complete gag and pol protein-coding regions from HIV-1 were substituted for the corresponding regions of a full-length M-MuLV clone to yield the chimeric plasmids pMoHIV-I, pMoHIV-III, and pMoHIV-IV, respectively. Cell lines which express the viral gag polyprotein were isolated for hybrids pMoHIV-I and pMoHIV-III. These cells produced viral particles which contained processed core proteins. Cleavage of the gag polyprotein in the viral particles was inhibited by the HIV-1 PR inhibitor L-687908, indicating that the viral PR is responsible for the observed processing. The hybrid virions were not infectious; analyses indicated that the viral particles contained little or no reverse transcriptase activity. In addition, particles produced by pMoHIV-III transfectants failed to package the viral genomic RNA. The cell line which expresses and processes the HIV-1 gag polyprotein is a safe and effective reagent for the in vivo evaluation of potential inhibitors of the HIV-1 PR.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709693      PMCID: PMC240951     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.

Authors:  J P Vacca; J P Guare; S J deSolms; W M Sanders; E A Giuliani; S D Young; P L Darke; J Zugay; I S Sigal; W A Schleif
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

2.  Inhibition of bacterially expressed HIV protease activity determined by an in vitro cleavage assay with MuLV Pr65gag.

Authors:  M Bu; S Oroszlan; R B Luftig
Journal:  AIDS Res Hum Retroviruses       Date:  1989-06       Impact factor: 2.205

3.  A second post-transcriptional trans-activator gene required for HTLV-III replication.

Authors:  J Sodroski; W C Goh; C Rosen; A Dayton; E Terwilliger; W Haseltine
Journal:  Nature       Date:  1986 May 22-28       Impact factor: 49.962

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Characterization of Moloney murine leukemia virus mutants with single-amino-acid substitutions in the Cys-His box of the nucleocapsid protein.

Authors:  C Méric; S P Goff
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

6.  Plaque assay techniques for murine leukemia viruses.

Authors:  W P Rowe; W E Pugh; J W Hartley
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

7.  Expression of the art/trs protein of HIV and study of its role in viral envelope synthesis.

Authors:  D M Knight; F A Flomerfelt; J Ghrayeb
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

8.  Active human immunodeficiency virus protease is required for viral infectivity.

Authors:  N E Kohl; E A Emini; W A Schleif; L J Davis; J C Heimbach; R A Dixon; E M Scolnick; I S Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Cis-acting sequences responsive to the rev gene product of the human immunodeficiency virus.

Authors:  A I Dayton; E F Terwilliger; J Potz; M Kowalski; J G Sodroski; W A Haseltine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1988

10.  Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.

Authors:  C Peng; B K Ho; T W Chang; N T Chang
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

View more
  6 in total

1.  BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

Authors:  B S Robinson; K A Riccardi; Y F Gong; Q Guo; D A Stock; W S Blair; B J Terry; C A Deminie; F Djang; R J Colonno; P F Lin
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 2.  Resistance to human immunodeficiency virus type 1 protease inhibitors.

Authors:  D Boden; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

3.  Constitutive production of nonenveloped human immunodeficiency virus type 1 particles by a mammalian cell line and effects of a protease inhibitor on particle maturation.

Authors:  L M Babé; C S Craik
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

4.  Chimeric human immunodeficiency virus type 1 containing murine leukemia virus matrix assembles in murine cells.

Authors:  Margaret Reed; Roberto Mariani; Liana Sheppard; Katja Pekrun; Nathaniel R Landau; Nay-Wei Soong
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Specificity of Rous sarcoma virus nucleocapsid protein in genomic RNA packaging.

Authors:  P Dupraz; P F Spahr
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

6.  Incorporation of human immunodeficiency virus type 1 Gag proteins into murine leukemia virus virions.

Authors:  C A Deminie; M Emerman
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.